HK1063004A1 - Oxalatoplatin and 5-fluorouracil for combination therapy of cancer - Google Patents

Oxalatoplatin and 5-fluorouracil for combination therapy of cancer

Info

Publication number
HK1063004A1
HK1063004A1 HK04104174A HK04104174A HK1063004A1 HK 1063004 A1 HK1063004 A1 HK 1063004A1 HK 04104174 A HK04104174 A HK 04104174A HK 04104174 A HK04104174 A HK 04104174A HK 1063004 A1 HK1063004 A1 HK 1063004A1
Authority
HK
Hong Kong
Prior art keywords
oxalatoplatin
fluorouracil
cancer
combination therapy
therapy
Prior art date
Application number
HK04104174A
Other languages
English (en)
Inventor
Masao Oguro
Junji Ohnishi
Original Assignee
Debiopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP30301594A external-priority patent/JPH08136536A/ja
Priority claimed from JP33403594A external-priority patent/JPH08169825A/ja
Priority claimed from JP11636995A external-priority patent/JPH08291061A/ja
Application filed by Debiopharm Sa filed Critical Debiopharm Sa
Publication of HK1063004A1 publication Critical patent/HK1063004A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK04104174A 1994-11-11 2004-06-10 Oxalatoplatin and 5-fluorouracil for combination therapy of cancer HK1063004A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP30301594A JPH08136536A (ja) 1994-11-11 1994-11-11 細胞分裂の観察方法及び抗癌剤の早期検定方法
JP33403594A JPH08169825A (ja) 1994-12-15 1994-12-15 抗癌剤の併用投与方法及び併用可能な抗癌剤
JP11636995A JPH08291061A (ja) 1995-04-18 1995-04-18 抗癌剤の併用投与方法及び併用可能な抗癌剤

Publications (1)

Publication Number Publication Date
HK1063004A1 true HK1063004A1 (en) 2004-12-10

Family

ID=27313136

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04104174A HK1063004A1 (en) 1994-11-11 2004-06-10 Oxalatoplatin and 5-fluorouracil for combination therapy of cancer

Country Status (5)

Country Link
US (2) US6518278B1 (es)
EP (2) EP0715854B1 (es)
DE (1) DE69531722T2 (es)
ES (1) ES2206478T3 (es)
HK (1) HK1063004A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9804013D0 (en) * 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6545010B2 (en) * 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
JP2007512318A (ja) 2003-11-25 2007-05-17 プラトコ・テクノロジーズ・（プロプライエタリー）・リミテッド 白金（ｉｉ）錯体並びに該錯体の製法及び使用
WO2006024897A1 (en) 2004-09-01 2006-03-09 Platco Technologies (Proprietary) Limited Preparation of platinum(ii) complexes
EP1827437B1 (en) 2004-12-15 2011-11-02 Novartis AG Combinations of therapeutic agents for treating cancer
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
RU2008135369A (ru) 2006-01-30 2010-03-10 Платко Текнолоджис (Проприэтэри) Лимитед (Za) Получение комплексов платины(ii)
EP2094268A2 (en) * 2006-05-26 2009-09-02 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
ES2373867T3 (es) 2007-03-02 2012-02-09 The University Of Wollongong Composiciones y procedimientos para el suministro de agentes anticancerosos.
TWI468188B (zh) * 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
WO2009139085A1 (ja) * 2008-05-12 2009-11-19 静岡県 抗腫瘍剤、キット及び癌治療方法
FR3035729B1 (fr) 2015-04-28 2020-11-27 Ateme Procede d'analyse d'une sequence video et equipement pour la mise en oeuvre du procede

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0612248B1 (en) * 1991-11-15 2003-08-20 Smithkline Beecham Corporation Composition containing cisplatin and topotecan as antitumor agent.
WO1994012193A1 (fr) * 1992-11-24 1994-06-09 Debiopharm S.A. Combinaison de cisplatine avec l'oxaliplatine

Also Published As

Publication number Publication date
EP0715854A2 (en) 1996-06-12
DE69531722T2 (de) 2004-07-01
US6518278B1 (en) 2003-02-11
EP0715854A3 (en) 1999-09-01
DE69531722D1 (de) 2003-10-16
US20040005365A1 (en) 2004-01-08
EP1369116A1 (en) 2003-12-10
ES2206478T3 (es) 2004-05-16
EP0715854B1 (en) 2003-09-10

Similar Documents

Publication Publication Date Title
ZA957483B (en) Compounds and methods for the treatment of cancer
EP0764030A4 (en) USE OF AUTOANTIBODIES FOR ANTI-TUMOR THERAPY AND PROPHYLAXIS
ZA979096B (en) Viral and cancer treatment
GB9518115D0 (en) Triazole derivatives and their use as therapeutic agents
EP0831904A4 (en) TREATMENT AND DIAGNOSIS OF PROSTATE CANCER
HK1063004A1 (en) Oxalatoplatin and 5-fluorouracil for combination therapy of cancer
IL114331A0 (en) Medical use of bromelain
IL114119A0 (en) Compositions and methods for the treatment of tumors
IL127739A0 (en) Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases
GB9219425D0 (en) Therapeutic agent and its use
GB9509572D0 (en) Cancer therapy
AU2512495A (en) Therapeutic phenoxyalkylazoles and phenoxyalkylazines
GB9308166D0 (en) Cancer therapy
EP0733365A3 (en) Use of benzoquinolin-3-one for the treatment and prevention of prostate cancer
GB9812550D0 (en) Tumour therapy and imaging
GB9606293D0 (en) Treatment of cancers and other tumours
IL136210A0 (en) Reagent for tumor therapy and/or imaging
ZA941939B (en) Therapeutic triazine compounds and use
GB9523066D0 (en) Compounds and their therapeutic use
GB9305693D0 (en) Therapeutic triazine compounds and use
GB9213592D0 (en) Cancer prevention and therapy
SI0971710T1 (en) Use of chelerythrine and radiation for tumor therapy
ZA937015B (en) Treatment and diagnosis of cancer
GB9119081D0 (en) Cancer therapy and compositions for use therein
GB9110422D0 (en) Cancer prevention and therapy